Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378849 | 0.97 | NOS3 (0.31) | NOS3NOS1NOS2ADRA2AADRA2B | |
| SCHEMBL31378666 | 0.87 | NOS3 (0.31) | NOS3NOS1NOS2ADRA2AADRA2B | |
| SCHEMBL31378881 | 0.83 | NOS3 (0.31) | NOS3NOS1NOS2ADRA2AADRA2B | |
| SCHEMBL6776899 | 0.78 | MAPK1 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL31378895 | 0.78 | — | — | |
| SCHEMBL31378798 | 0.78 | — | — | |
| SCHEMBL31378636 | 0.74 | ALDH1A1 (0.37) | ADRA2A | |
| SCHEMBL29791251 | 0.72 | ADRA2A (0.47) | NOS3NOS1NOS2ADRA2AADRA2B | |
| SCHEMBL31220065 | 0.72 | ADRA2A (0.51) | NOS3NOS1NOS2ADRA2AADRA2B | |
| SCHEMBL5464319 | 0.72 | ADRA2A (0.47) | NOS3NOS1NOS2ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | NOS3 1687/4885NOS1 1416/4885NOS2 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.